2-(Cyclopropylamino)-5,6-dichloro-1H-benzimidazole | 193527-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(Cyclopropylamino)-5,6-dichloro-1H-benzimidazole
• 英文别名: 2-cyclopropylamino-5,6-dichlorobenzimidazole；2-(Cyclopropylamino)5,6-dichloro-1H-benzimidazole；2-(cyclopropylamino)-5,6dichloro-1H-benzimidazole；5,6-dichloro-N-cyclopropyl-1H-benzimidazol-2-amine
• CAS: 193527-03-6
• 化学式: C₁₀H₉Cl₂N₃
• 分子量: 242.108
• InChiKey: DHXXBIRDKFQGCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(Cyclopropylamino)-5,6-dichloro-1H-benzimidazole 在 三氟甲磺酸三甲基硅酯 、 sodium carbonate 作用下， 以 甲醇 、 乙醇 、 1,2-二氯乙烷 为溶剂， 反应 16.5h， 生成 2-cyclopropylamino-5,6-dichloro-1-(β-L-erythrofuranosyl)benzimidazole
  参考文献：
  名称：

  Synthesis and Antiviral Evaluation of Halogenated β-d- and -l-Erythrofuranosylbenzimidazoles

  摘要：

  A series of 2-substituted benzimidazole D- and L-erythrofuranosyl nucleosides were synthesized and tested for activity against herpesviruses and for cytotoxicity. The D-nucleosides 2,5,6-trichloro-1-(beta-D-erythrofuranosyl)benzimidazole (8a) and 2-bromo-5,6-dichloro-1-(beta-D-erythrofuranosyl)benzimidazole (8b) were prepared by coupling 1,2,3,-tri-O-acetyl-beta-D-erythrofuranose (D-6) with the appropriate benzimidazole, followed by removal of the acetyl protecting groups. The 2-isopropylamino (9), 2-cyclopropylamino (10), and 2-mercaptobenzyl (11) derivatives were synthesized by nucleophilic displacements of the C-2 chlorine in the benzimidazole moiety of 8a. The D-nucleoside 4-bromo-5,6-dichloro-2-isopropylamino-1-(beta-D-erythrofuranosyl)benzimidazole (17) was prepared by coupling D-6 with the appropriate benzimidazole. The L-erythrofuranosyl derivatives, 5,6-dichloro-2-isopropylamino-1-(beta-L-erythrofuranosyl)benzimidazole (21a), its 2-cyclopropylamine analogue (21b), and the 2-isopropylamino analogue (4c). In comparison, 8a was 15-fold more active against HCMV than 4a, and 8b was 4-fold more active against HCMV than 4b. The 5,6-dichloro-2-isopropylamino-1-(beta-L-erythrofuranosyl)benzimidazole (21a) was less active than 4c, which is now in clinical trials for HCMV infection. Both 8a,b had comparable HCMV activity to 4c. Mode of action studies with the D-erythrose analogues established that 8b acted by inhibition of viral DNA processing whereas 9 and 10 may act via a different mechanism. The lack of a 5'-hydroxymethyl group in all members of this series established that antiviral activity occurred without 5'-phosphorylation, a feature required for the activity of most nucleoside analogues.

  DOI：

  10.1021/jm990195p
• 作为产物：
  描述：

  4,5-二氯邻苯二胺 、 异硫氰酸环丙酯 在 吡啶 、 1-环已基-2-吗啉乙基碳二亚胺对甲苯磺酸盐 作用下， 反应 1.0h， 以70%的产率得到2-(Cyclopropylamino)-5,6-dichloro-1H-benzimidazole
  参考文献：
  名称：

  Synthesis and Antiviral Evaluation of Halogenated β-d- and -l-Erythrofuranosylbenzimidazoles

  摘要：

  A series of 2-substituted benzimidazole D- and L-erythrofuranosyl nucleosides were synthesized and tested for activity against herpesviruses and for cytotoxicity. The D-nucleosides 2,5,6-trichloro-1-(beta-D-erythrofuranosyl)benzimidazole (8a) and 2-bromo-5,6-dichloro-1-(beta-D-erythrofuranosyl)benzimidazole (8b) were prepared by coupling 1,2,3,-tri-O-acetyl-beta-D-erythrofuranose (D-6) with the appropriate benzimidazole, followed by removal of the acetyl protecting groups. The 2-isopropylamino (9), 2-cyclopropylamino (10), and 2-mercaptobenzyl (11) derivatives were synthesized by nucleophilic displacements of the C-2 chlorine in the benzimidazole moiety of 8a. The D-nucleoside 4-bromo-5,6-dichloro-2-isopropylamino-1-(beta-D-erythrofuranosyl)benzimidazole (17) was prepared by coupling D-6 with the appropriate benzimidazole. The L-erythrofuranosyl derivatives, 5,6-dichloro-2-isopropylamino-1-(beta-L-erythrofuranosyl)benzimidazole (21a), its 2-cyclopropylamine analogue (21b), and the 2-isopropylamino analogue (4c). In comparison, 8a was 15-fold more active against HCMV than 4a, and 8b was 4-fold more active against HCMV than 4b. The 5,6-dichloro-2-isopropylamino-1-(beta-L-erythrofuranosyl)benzimidazole (21a) was less active than 4c, which is now in clinical trials for HCMV infection. Both 8a,b had comparable HCMV activity to 4c. Mode of action studies with the D-erythrose analogues established that 8b acted by inhibition of viral DNA processing whereas 9 and 10 may act via a different mechanism. The lack of a 5'-hydroxymethyl group in all members of this series established that antiviral activity occurred without 5'-phosphorylation, a feature required for the activity of most nucleoside analogues.

  DOI：

  10.1021/jm990195p

文献信息

• [EN] BENZIMIDAZOLE DERIVATIVES<br/>[FR] DERIVES DE BENZIMIDAZOLE
  申请人：GLAXO GROUP LIMITED

  公开号：WO1998035977A1

  公开（公告）日：1998-08-20

  (EN) The present invention relates to certain benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses.(FR) La présente invention concerne certains dérivés de benzimidazole, ainsi que leur utilisation en thérapie médicale, particulièrement dans le traitement ou la prophylaxie d'infections virales telles que les infections aux herpèsvirus.

  (中) 本发明涉及某些苯并咪唑衍生物及其在医疗治疗中的应用，特别是用于治疗或预防病毒感染，如由疱疹病毒引起的感染。(FR) 本发明涉及某些苯并咪唑衍生物及其在医疗治疗中的应用，特别是用于治疗或预防病毒感染，如由疱疹病毒引起的感染。
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSES THERAPEUTIQUES
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：WO1996001833A1

  公开（公告）日：1996-01-25

  (EN) The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.(FR) L'invention concerne des dérivés de benzimidazole ainsi que leur utilisation en thérapie médicale, notamment dans le traitement ou la prophylaxie d'infections virales telles que celles provoquées par les herpèsvirus. L'invention concerne également la préparation des dérivés de benzimidazole ainsi que des formulations pharmaceutiques les contenant.

  (中) 本发明涉及苯并咪唑衍生物及其在医学治疗中的应用，特别是用于治疗或预防由疱疹病毒引起的病毒感染。本发明还涉及苯并咪唑衍生物的制备以及含有它们的制药配方。
• Therapeutic compounds
  申请人：——

  公开号：US20010003744A1

  公开（公告）日：2001-06-14

  The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.

  本发明涉及苯并咪唑衍生物及其在医疗治疗中的应用，特别是用于治疗或预防病毒感染，例如由疱疹病毒引起的感染。本发明还涉及苯并咪唑衍生物的制备以及含有它们的制药配方。
• Antiviral benzimidazole nucleoside analogues and method for their
  申请人：Glaxo Wellcome Inc.

  公开号：US05998605A1

  公开（公告）日：1999-12-07

  The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.

  本发明涉及苯并咪唑衍生物及其在医疗治疗中的应用，特别是用于治疗或预防由疱疹病毒引起的病毒感染。本发明还涉及苯并咪唑衍生物的制备以及含有它们的制药配方。
• Benzimidazole derivatives for the treatment of viral infections
  申请人：The Regents of the University of Michigan

  公开号：US06413938B1

  公开（公告）日：2002-07-02

  According to a first aspect of the invention there is provided compounds of formula (I): wherein: R1 is hydroxy; O-acetyl; or a halo atom; R2 is hydroxy; O-acetyl; or a halo atom; R3 is hydrogen; a halo atom; azido; C2-6alkenyl; C2-6alkynyl; C6-14aryl C2-6alkenyl; C6-14arylC2-6alkynyl —NR8R9 (where R8 and R9 may be the same or different and are hydrogen, C1-8alkyl, cyanoC1-8alkyl, hydroxyC1-8alkyl, haloC1-8alkyl, C3-7cycloalkyl, C1-8alkylC3-7cycloalkyl, C2-6alkenyl, C3-7cycloalkylC1-8alkyl, C2-6alkynyl, C6-14aryl, C6-14arylC1-8alkyl, heterocycleC1-8alkyl, C1-8alkylcarbonyl, C6-14arylsulfonyl, C1-8alkysulfonyl, or R8R9 together with the N atom to which they are attached form a 3,4,5 or 6 membered heterocyclic ring); —OR10 (where R10 is hydrogen, C1-8alkyl, C6-14aryl, or C6-14arylC1-8alkyl, C2-6alkenyl, C2-6alkynyl, C6-14aryl C2-6alkenyl or C6-14arylC2-6alkynyl); or —SR11 (where R11 is hydrogen, C1-8alkyl, C6-14aryl, or C6-14arylC1-8alkyl).

  根据本发明的第一个方面，提供了以下式子(I)的化合物：其中：R1是羟基；O-乙酰基；或卤素原子；R2是羟基；O-乙酰基；或卤素原子；R3是氢；卤素原子；叠氮基；C2-6烯基；C2-6炔基；C6-14芳基C2-6烯基；C6-14芳基C2-6炔基—NR8R9（其中R8和R9可以相同或不同，并且是氢，C1-8烷基，氰基C1-8烷基，羟基C1-8烷基，卤素C1-8烷基，C3-7环烷基，C1-8烷基C3-7环烷基，C2-6烯基，C3-7环烷基C1-8烷基，C2-6炔基，C6-14芳基，C6-14芳基C1-8烷基，杂环C1-8烷基，C1-8烷基羰基，C6-14芳基磺酰基，C1-8烷基磺酰基或R8R9与它们连接的N原子形成3,4,5或6成员杂环环）；—OR10（其中R10是氢，C1-8烷基，C6-14芳基或C6-14芳基C1-8烷基，C2-6烯基，C2-6炔基，C6-14芳基C2-6烯基或C6-14芳基C2-6炔基）；或—SR11（其中R11是氢，C1-8烷基，C6-14芳基或C6-14芳基C1-8烷基）。